newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

  • AEON Biopharma scheduled an FDA Type 2a meeting for November 19, 2025, to review its analytical development plan & initial data for ABP-450.
  • Positive biosimilarity data submitted to the FDA confirms ABP-450 has identical amino-acid sequencing & highly similar functional characteristics to BOTOX®.
  • LC-MS analysis showed a 100% amino-acid sequence match between ABP-450 & BOTOX®, with sequence coverage of 93–99% across the botulinum toxin type A complex.
  • Two financing transactions announced in November 2025 include a $6 million PIPE financing & a proposed Daewoong Pharmaceutical note exchange.
  • These financing deals are expected to reduce AEON's outstanding debt by more than 90%, strengthen its balance sheet, & extend its cash runway into the second quarter of 2026.
  • The new capital is projected to accelerate the ABP-450 biosimilar program by up to six months.
  • As of September 30, 2025, AEON reported $5.9 million in cash & cash equivalents, excluding the proceeds from the November financing.
  • The company reported a net loss of $4.5 million for the three months ended September 30, 2025, & a net loss of $2.1 million for the nine-month period.
  • AEON holds exclusive U.S. development & distribution rights for ABP-450, which is manufactured by Daewoong Pharmaceutical in an FDA-approved facility.
  • ABP-450 is currently approved as a biosimilar in India, Mexico, & the Philippines, with a global manufacturing platform approved in 69 countries.